Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00702260 · ClinicalTrials.gov registry record · NA

Bioequivalency Study of Ramipril 10 mg Capsules Under Fed Conditions

A NA study of Hypertension, sponsored by Roxane Laboratories.

Completed
Registry status
NA
Development phase
39
Enrollment target
1
Study location

NCT00702260 is a NA study of Hypertension that has completed, run by Roxane Laboratories. The registered enrollment target is 39 participants, below the 3,507-participant average among 470 other Hypertension trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00702260, a NA study of Hypertension, has completed, sponsored by Roxane Laboratories.

COMPLETED
Registry status
NA
Development phase
39 participants
Enrollment target
1
Study location

Study Summary

The objective of this study was to prove the bioequivalence of Ramipril 10 mg capsules under fed conditions.

Conditions Studied

Interventions

  • DRUG Ramipril

Study Locations (1)

Texas

  • CEDRA Clinical Research, LLC - Austin

Trial Details

FieldValue
Enrollment Target 39 participants
Start Date 2005-01
Est. Completion 2005-01
Phase NA

Sponsor

Roxane Laboratories

93 total trials

What the Registry Record Tells You About NCT00702260

The ClinicalTrials.gov registry entry for NCT00702260 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 39 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 3,507-participant average among 470 other Hypertension trials with a reported enrollment target (99% lower). The listed sponsor is Roxane Laboratories, which has 93 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Hypertension appearing as the primary indexed condition, and to 1 intervention - of which Ramipril is the first listed.

NCT00702260 reports 1 study location spanning 1 distinct geographic area - top geographies include Texas.

Frequently Asked Questions

What is clinical trial NCT00702260 about?

NCT00702260 is a clinical study titled "Bioequivalency Study of Ramipril 10 mg Capsules Under Fed Conditions". The objective of this study was to prove the bioequivalence of Ramipril 10 mg capsules under fed conditions.

What is the current status of trial NCT00702260?

This trial is currently completed. It is a NA study. The enrollment target is 39 participants. The study started on 2005-01. Estimated completion is 2005-01.

What conditions does trial NCT00702260 study?

This clinical trial studies the following conditions: Hypertension.

What interventions are being tested in trial NCT00702260?

The interventions under investigation include: Ramipril (DRUG).

Who is sponsoring clinical trial NCT00702260?

This trial is sponsored by Roxane Laboratories, which has 93 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00702260 being conducted?

This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Hypertension

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.